Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026

The early ALARIC findings cover four patients treated with D8 alone, with a median five-month follow-up.

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) announced published abstracts covering obe-cel and ALARIC clinical findings for presentation at the ASH Annual Meeting. The meeting runs December 12–15, 2026, in New Orleans.

In adults with relapsed/refractory B-cell acute lymphoblastic leukemia, obe-cel responses measured by measurable residual disease, or cancer remaining after treatment, deepened beyond month one. Patients achieving delayed negativity had outcomes comparable to early responders. In a FELIX patient subset, agreement between two tests supported using commercially available quantitative PCR to monitor obe-cel levels.

In the phase 1 ALARIC trial for relapsed/refractory systemic AL amyloidosis, all first four patients treated with D8 CAR-T cells alone achieved rapid complete blood-related responses. Tolerability was good, with encouraging organ-function improvements at a median five-month follow-up.

Positive

• Minor pointObe-cel residual-disease responses deepened beyond month one; delayed-negative patients had outcomes comparable to early responders.
• Minor pointAssay agreement in a FELIX patient subset supported commercially available quantitative PCR for clinical obe-cel monitoring.
• Minor pointD8 alone produced rapid complete haematological responses in all first four patients treated in phase 1 ALARIC.
• Minor pointD8 tolerability was good, with encouraging organ-function improvements at a median five-month follow-up.

Negative

• None.

Key Figures

Complete hematological response: 4 of 4 patients Median follow-up: 5 months

Complete hematological response

4 of 4 patients

D8 alone in the phase 1 ALARIC trial

Median follow-up

5 months

First four patients treated with D8 alone

Previous Clinical trial Reports

1 past event · Latest: May 21

Same Type 1 event

1. May 21

   FELIX clinical data

   24h Move

   +3.0%

   Earlier FELIX EMD analysis reported remission and duration-of-response findings for obe-cel in adult R/R B-ALL.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

measurable residual disease, droplet digital pcr, quantitative pcr, bcma, +1 more

5 terms

measurable residual disease medical

"a deepening of measurable residual disease (MRD) response"

Measurable residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment and can be detected using sensitive laboratory tests even when scans look clear. For investors, MRD matters because it's a strong early signal of how well a therapy works, can influence clinical trial success, regulatory decisions and future sales, and helps predict whether disease will come back much like spotting embers after a put-out fire.

droplet digital pcr technical

"droplet digital PCR (ddPCR) and quantitative PCR (qPCR) assays"

Droplet digital PCR is a laboratory method that splits a DNA or RNA sample into thousands of tiny droplets and runs many parallel tests so you can count exactly how many droplets contain the target genetic material. Like checking which bulbs in a giant string are lit, it gives a precise, highly sensitive measure of low-level DNA/RNA signals. Investors care because this accuracy enables better diagnostics, patient monitoring, and drug development decisions, and it supports sales of specialized instruments, assays, and recurring consumables.

quantitative pcr technical

"droplet digital PCR (ddPCR) and quantitative PCR (qPCR) assays"

Quantitative PCR (qPCR) is a laboratory method that amplifies and measures the amount of specific genetic material (DNA or RNA) in a sample, producing a numerical result rather than a simple yes/no. Investors care because qPCR underpins diagnostic tests, vaccine and drug development, and quality control for biotech products—think of it like a molecular “copy-and-count” tool that shows how much of a target is present, which can affect regulatory approval, market demand, and company valuation.

bcma medical

"assessing BCMA and BCMA/CD19 CAR-T"

BCMA (B‑cell maturation antigen) is a protein that sits on the surface of certain cancer cells, especially those from a type of blood cancer, and acts like a visible target for therapies. Investors care because drugs that successfully hit this target—using approaches like engineered immune cells or targeted antibodies—can change treatment options and drive revenue, while trial results, safety, and approval prospects directly affect a company’s valuation.

car-t medical

"BCMA and BCMA/CD19 CAR-T for the treatment"

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 12-15, 2026, in New Orleans, Louisiana.

Abstract 4498 – Oral Presentation
Title: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): A deepening of measurable residual disease (MRD) response and recovery from cytopenias
Session name: Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL
Presentation date and time: December 12, 2026; 5:00 - 5:15 PM ET
Presentation room: MCCNO - 265-268
Publication number: 377
Presenting author: Elias Jabbour, MD; D.B. Lane Cancer Research Fund Distinguished Professor in Leukemia Research; Section Chief Acute Lymphoblastic Leukemia; MD Anderson Cancer Center, Houston, Texas

Summary: In an evaluation of efficacy, safety and hematologic recovery during the first three months after infusion to define early clinical expectations following obe-cel treatment, MRD responses continued to deepen beyond month one, with patients who achieved delayed MRD negativity experiencing outcomes comparable to early responders. These findings may help define early clinical expectations following obe-cel treatment and inform patient management strategies.

Abstract 273 – Poster Presentation
Title: Analytical and clinical concordance of droplet digital PCR (ddPCR) and quantitative PCR (qPCR) assays to monitor obecabtagene-autoleucel (obe-cel) presence in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
Session Name: 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III
Presentation date and time: December 14, 2026; 6:00 PM - 8:00 PM ET
Presentation room: MCCNO - Hall F
Publication number: 5094
Presenting author: Aaron Logan, MD; Professor of Medicine; Director, Cellular Therapy Program; Division of Hematology, Blood and Marrow Transplant, and Cellular Therapy; University of California, San Francisco (UCSF), San Francisco, California

Summary: Recently, a novel qPCR assay was developed, validated, and made available in a reference laboratory to enable monitoring of obe-cel levels. Concordance between the ddPCR and qPCR assay results within this subset of patients from FELIX is sufficient and acceptable to support the use of the commercially available qPCR assay for patients in clinical practice.

Abstract 11291 – Poster Presentation
Title: Initial results of the phase 1 UKMRA ALARIC trial assessing BCMA and BCMA/CD19 CAR-T for the treatment of relapsed/refractory AL amyloidosis
Session name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Presentation date and time: December 12, 2026, 5:30-7:30 PM
Presentation room: MCCNO - Hall F
Publication number: 2185
Presenting author: Lydia Lee, Associate Professor, UCL Cancer Institute; Consultant Haematologist, UCLH

Summary: ALARIC is a phase 1 trial evaluating Fab-based BCMA (D8) CAR-T cells, alone or co-transduced with a CD19 CAR (AUTO8), in relapsed/refractory systemic AL amyloidosis. All of the first four patients treated with D8 alone achieved rapid complete haematological response, with good tolerability and encouraging improvements in organ function at a median five-month follow-up.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding Autolus’ future expectations, plans and prospects, including the therapeutic potential and expected clinical benefits of obe-cel and BCMA/CD19 CAR T therapy. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks identified in the section titled “Risk Factors” in Autolus’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC), on March 26, 2026, and its subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the SEC. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus’ views as of any date subsequent to the date of this press release.

Contact:

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Autolus report about obe-cel responses after the first month?

Responses measured by measurable residual disease continued to deepen beyond month one after obe-cel infusion. In the evaluation covering the first three months, adults with relapsed/refractory B-cell acute lymphoblastic leukemia who achieved delayed residual-disease negativity experienced outcomes comparable to early responders.

What were Autolus's initial ALARIC trial results?

All of the first four patients treated with D8 alone achieved rapid complete haematological responses in the phase 1 ALARIC trial. The patients had relapsed/refractory systemic AL amyloidosis. Tolerability was good, with encouraging improvements in organ function at a median five-month follow-up.